Syntis Bio
MILTON, MA · Biotechnology · 25 employees
Syntis Bio is a clinical-stage biopharmaceutical company developing oral therapies that harness the small intestine’s unique biology to provide accessible, effective and sustainable solutions across the healthcare spectrum, from rare genetic disorders to the world’s most prevalent conditions. Syntis is rapidly advancing a pipeline of oral therapies engineered for optimization in the small intestin
Funding history
- Venture - Series Unknown — $25.0M — Jul 2025
- Series A — $33.0M — Jul 2025
- Venture - Series Unknown — $6.3M — Jan 2025
- Venture - Series Unknown — $15.4M — Jan 2023
- Venture - Series Unknown — $15.4M — Aug 2022
Recent signals
- Jun 09, 2026: Syntis Bio Appoints Matthew Dallas as Chief Financial Officer
- Mar 03, 2026: Syntis Bio Appoints David Rosenbaum as Chief Development Officer and Christo Shalish as Chief Business Officer
- Jul 02, 2025: Raised $25.0M in Venture - Series Unknown
- Jul 01, 2025: Raised $33.0M in Series A
- Jan 27, 2025: Raised $6.3M in Venture - Series Unknown
- Jan 17, 2023: Raised $15.4M in Venture - Series Unknown
- Aug 17, 2022: Raised $15.4M in Venture - Series Unknown
See plans & pricing → Track Syntis Bio’s funding, hiring, and signals — with verified contacts — on Fundz.